A new MSK study reveals how genes activate across vast distances inside a cell, identifying a new form of cell death that could open new opportunities for cancer therapy. The research also uncovers hidden genetics involved in autism and develops an AI tool to predict a cell's fate.
A large-scale study analyzing routine clinical data from nearly 60,000 cancer patients reveals new insights into cachexia. The findings show that cachexia can be predicted using routine data, allowing for timely support and interventions. This breakthrough could help improve patient outcomes and quality of life.
Researchers from Memorial Sloan Kettering Cancer Center have made several groundbreaking discoveries in the field of MSK research, including the role of immune cells in fueling triple-negative breast cancer and the development of a new strategy to combat leptomeningeal metastases. Additionally, the study found that trastuzumab deruxtec...
Researchers at Memorial Sloan Kettering Cancer Center identify a critical inflammatory signaling pathway and its role in protecting healthy cells from immune response damage. The discovery opens new avenues for understanding diseases where inflammation runs amok, including cancer, inflammatory bowel disease, and asthma.
Researchers at Memorial Sloan Kettering Cancer Center have developed nanoparticles that can selectively eliminate a small population of immune cells found to drive fibrosis, potentially paving the way for new approaches against immunotherapy-resistant tumors and fibrotic diseases. The approach could make immunotherapy work for more pat...
Researchers at Memorial Sloan Kettering Cancer Center have discovered a structural weakness in extrachromosomal DNA, a type of rogue DNA found in aggressive cancers, which can be targeted therapeutically. Blocking a single repair protein, polymerase theta, causes the DNA to fall apart, suggesting a new approach to treating cancer.
A metabolite called DAHB boosts immune cells against cancer, predicting tumor success and showing promise in small cell lung cancer treatment. Researchers also found that tumor CD19 levels can predict the success of CAR T cell therapy and identified a new targeted drug combination.
Researchers at Memorial Sloan Kettering Cancer Center used AI to design better CAR T cell therapies by recognizing specific proteins on cancer cells. The AI approach outperformed existing binders in a proof-of-concept study, leading to a better understanding of why some cancer-targeting proteins work well and others fail.
Researchers at MSK have identified a protein called integrin alpha-5 as a key driver of lung metastasis across several cancer types. A new three-drug combination that includes epcoritamab, rituximab, and lenalidomide is effective in almost all patients newly diagnosed with follicular lymphoma, offering a potential alternative to chemot...
Researchers from Memorial Sloan Kettering Cancer Center discovered ZFP36L2, a protein that regulates stem cell renewal and repair in the gut. Colorectal cancer cells exploit this process to spread to new organs through metastasis. Disrupting ZFP36L2 may compromise cancer cells' ability to form new tumors.
New research from Memorial Sloan Kettering Cancer Center sheds light on leukemia resistance to promising new drugs and the role of bone hardness in the immune battle against metastasis. A telehealth tobacco treatment program also shows promise in helping cancer patients quit smoking.
Researchers have identified a new strategy to prevent T cell exhaustion and boost immunotherapy by blocking MEK signaling. This approach has shown promise in lab models, enabling T cells to persist under harsh tumor conditions. However, the effectiveness of this treatment may vary among patients due to the complexity of T cell exhaustion.
The research reveals how WNT signals guide embryonic cells toward specialized identities, with implications for cancer biology. Cells receive a push from WNT to start down the path toward becoming muscles, bones, organs, and connective tissue, but then receive a second layer of instruction that defines their final outcome.
A team of scientists found that a small subset of T cells called stem T cells are responsible for making new T cells and replenishing them in chronic disease. These rare stem T cells express the protein LEF1, which is key to their persistence. Boosting LEF1-positive cells overcame T cell exhaustion in chronic infection, while removing ...
Researchers at MSK discovered that tumors with low levels of NF2, a tumor suppressor gene, are less likely to respond to immunotherapy. They also found that combinations of VEGFR-TKIs and immunotherapies can be effective but have limited long-term benefits due to paradoxical effects of hypoxia on treatment response.
Researchers at Memorial Sloan Kettering Cancer Center found that the tail region of mRNAs helps fold thousands of critical regulatory proteins correctly. This discovery sheds new light on fundamental biology and has practical implications for laboratory research.
Researchers at Memorial Sloan Kettering Cancer Center have uncovered promising combination therapies for a rare childhood brain tumor by analyzing patient samples, cell models, and laboratory data. The study found that cancer cells can develop workarounds to evade targeted RAS therapies, highlighting the need for new treatment strategies.
Researchers developed a new CAR T cell therapy targeting U5 snRNP200 protein found on AML cells but not healthy blood cells. The approach harnesses antibodies discovered in patients who went into long-term remission after bone marrow transplant, proving effective against several types of leukemia.
MSK researchers showcased innovative therapeutic advances for HER2-driven rectal and KRAS-driven pancreatic cancers, as well as a promising mRNA vaccine. CAR T cell therapies targeting uPAR showed promise in shrinking solid tumors and overcoming treatment resistance.
Researchers found that disruption of communication between cancer-causing cells and surrounding healthy tissue can prevent tumor growth. The study suggests that early intervention may be possible, as the transformed environment is reversible if caught early enough.
A recent study published in Cell reveals the molecular mechanisms underlying the transformation of benign pancreatic cells into malignant tumors. Researchers identified a subset of precancerous cells that closely resemble tumor cells, characterized by high oncogenic drive and strongly activated tumor-suppressors. This discovery offers ...
Researchers develop CAR T cells designed to target both cancer cells and supportive cells in the tumor microenvironment, bearing the surface protein uPAR. The new approach shows significant power to fight cancer with limited impact on other healthy tissues and cells.
Researchers at Memorial Sloan Kettering Cancer Center discovered that skin stem cells possess a remarkable form of inflammatory memory that can last over a year. This finding has implications for understanding how repeated inflammation affects skin aging and disease susceptibility. The study used MSK-IMPACT, a tumor sequencing test, to...
Researchers develop new approach to prevent chemotherapy-related leukemia by analyzing blood samples from four clinical trials, showing a 26-36% reduction in blood cell growth with mutated TP53 gene. They also discover that monoclonal antibodies can turn neutrophils into cancer killers and induce tumor eradication in preclinical models.
A new study from Memorial Sloan Kettering Cancer Center reveals that analyzing a patient's genomic profile can predict breast cancer resistance to CDK4/6 inhibitors. The researchers found that inheriting a BRCA2 mutation and other genetic alterations increase the likelihood of resistance. This discovery provides a new strategy for pred...
New MSK research reveals that the TCA cycle's waste-management function may present an opportunity against cancer, microplastics impair immune 'housekeeping' functions and TOX plays different roles in different immune cells. A new combination approach for treating advanced kidney cancer after immunotherapy has also been identified.
Researchers at Memorial Sloan Kettering Cancer Center investigate ferroptosis as a potential target for cancer treatment. They also develop an AI model to analyze country-specific factors driving global cancer outcomes. Additionally, the institution introduces an AI-based incident analysis approach to improve patient safety.
Researchers from Memorial Sloan Kettering Cancer Center reveal the origins of Thetis cells, which play a crucial role in teaching immune system tolerance. The team used single-nucleus DNA sequencing to shed light on pancreatic cancer evolution and identify genetic changes that occur earlier or later in disease progression.
A small subset of highly plastic cancer cells drives cancer progression and treatment resistance, study finds. Targeting these cells may make current treatments more effective and prevent aggressive tumors from forming.
New MSK research reveals that the gut uses immune cells to sense bacteria, triggering protective responses. A subtype of glioma-associated macrophages may play a pivotal role in tumor progression. Additionally, reduced thyroid surgery is an option for some patients.
Researchers discovered that cancer cells lower their surface tension to evade immune detection, making them harder to attack. By understanding this process, scientists hope to develop new treatments to prevent metastasis and eliminate dormant cancer cells.
Researchers from MSK discovered that two distinct subtypes of regulatory T cells play opposing roles in colorectal cancer, with one restraining tumor growth and the other fueling it. The study suggests that selective approaches to targeting these cells could improve immunotherapy treatment for most patients with colorectal cancer.
Researchers at MSK found that Foxp3 degradation can inhibit cancer growth and enhance immune response. They also developed a system to detect loss of heterozygosity during gene editing, which is a common problem in DNA double-strand breaks.
Researchers at MSK Cancer Center developed laboratory models of VEXAS syndrome, a confounding inflammatory disease. They identified new insights into the disease's mechanisms and potential therapeutic targets by mapping molecular circuitry and blocking parts of the
A new study from Memorial Sloan Kettering Cancer Center identifies unique genetic signatures in cancer patients of non-European ancestry and finds adding immunotherapy can boost effectiveness for hard-to-treat follicular lymphomas. Additionally, researchers discover a web-based system to report head-and-neck cancer concerns, leading to...
Researchers at MSK presented new studies on three phase 1 trials testing innovative treatment approaches for advanced solid tumors, including lung and pancreatic cancers. The studies explored personalized treatments for patients with mismatch repair deficiency, a defect that may guide immunotherapy.
A new mathematical model helps understand how the immune system shapes cancer development, with implications for immunotherapies and cancer vaccines. The research identifies specific repetitive DNA elements that mimic viral patterns, potentially serving as a general defense against infections.
Researchers at MSK presented two clinical trials looking at the benefits of lowering radiation doses for patients with throat cancer. The studies found that reducing treatment can protect the immune system and help patients recover quickly. Additionally, a trial on breast cancer treatment showed that accelerated partial breast irradiat...
MSK researchers have developed a new method to study treatment resistance in high-grade serous ovarian cancer. By analyzing blood samples from 18 patients, they identified subpopulations of cancer cells with distinctive genetic features that contribute to recurrence. This approach may help develop targeted treatments for specific vulne...
Chrysothemis Brown, an immunologist at Memorial Sloan Kettering Cancer Center, has been selected as a 2025 Freeman Hrabowski Scholar to pursue curiosity-driven research on early life immune development and tolerance. The award supports her lab's work in understanding immune tolerance and developing new treatments for immune-related dis...
New MSK research explores the importance of tumor location in metastasis, regulatory T cells' role in pain management, and the effectiveness of proton therapy for leptomeningeal metastasis. The study found that different organ sites select for different cell types present in primary tumors, affecting their viability.
A new study from Memorial Sloan Kettering Cancer Center shows the Make-an-IMPACT program improves global access to genomic testing for pediatric cancer patients. The program helps develop an experimental antibody that shows promise against metastatic cancer. Researchers also shed light on the origins of ERG-driven prostate cancer and f...
Researchers at Memorial Sloan Kettering Cancer Center have identified two transcription factors, SP5 and SP8, that play a crucial role in the formation of primary cilia. The discovery could lead to new treatments for diseases caused by missing or malfunctioning primary cilia, which affect millions worldwide. By understanding how these ...
A new resource, EuPRI, maps RNA sequences for nearly 35,000 RBPs across nearly 700 species, offering insights into evolutionary history and potential therapeutic targets. Researchers also uncover how oxygen sensors regulate ferroptosis and how a specific transcription factor influences natural killer cell responses.
A team of researchers at Memorial Sloan Kettering Cancer Center has made a groundbreaking discovery about why genetically engineered immune cells sometimes fail to fully destroy tumors. They found that FAS ligand, produced by the immune cells themselves, causes self-destruction and reduces therapy's effectiveness.
A new study found that over 65% of ovarian cancer tumors exhibit whole-genome doubling, making them more resistant to treatments. WGD-high tumors suppress the immune response by repressing key pathways.
Researchers from Memorial Sloan Kettering Cancer Center developed a new approach to induce mutations in resistant cancer cells, making them sensitive to immunotherapy. The study showed positive outcomes in patients over 90 with lung cancer who underwent surgery.
Researchers at Memorial Sloan Kettering Cancer Center have gained new insights into how cancer spreads, revealing that metastatic cells can endlessly divide and produce diverse cell types. This flexibility allows them to adapt to various environments and develop resistance to treatments.
Scientists at MSK found that certain metabolites play a key role in driving differentiation in stem cells, potentially leading to improved tissue regeneration and healing for conditions involving chronic inflammation. APOBEC3 enzymes were linked to breast cancer resistance and growth, with implications for treatment.
A recent study published in Nature Genetics sheds light on the genetic changes that occur when cancer spreads from a primary tumor to new sites throughout the body. The research team found that whole-genome duplication is the most common genetic event during metastasis, occurring in nearly one-third of patients.